Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study
- 3 October 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 21 (2), e49-e61
- https://doi.org/10.1016/j.clcc.2021.09.001
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 24 references indexed in Scilit:
- Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinomaEuropean Journal of Cancer, 2010
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnnals of Oncology, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal CancerJournal of Clinical Oncology, 2009
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004
- Multivariate longitudinal models for complex change processesStatistics in Medicine, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993